-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 OD0Xs/g2lsFvPR0oL0KY/VX58sS1cHJFEel2eBUxH1SxEnwbn8NuRTI52jiKLnVo
 SEmSGU58UCoxaniOD7zyHg==

<SEC-DOCUMENT>0001144204-07-005886.txt : 20070208
<SEC-HEADER>0001144204-07-005886.hdr.sgml : 20070208
<ACCEPTANCE-DATETIME>20070208150052
ACCESSION NUMBER:		0001144204-07-005886
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070208
FILED AS OF DATE:		20070208
DATE AS OF CHANGE:		20070208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		07592128

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT WEIZMANN BUILDING 3
		CITY:			REHOVOT76100 ISRAEL
		STATE:			L3

	MAIL ADDRESS:	
		STREET 1:		KIRYAT WEIZMANN BUILDING 3
		CITY:			REHOVOT76100 ISRAEL
		STATE:			L3
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v064897_6k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      February 8, 2007</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>XTL
      Biopharmaceuticals Ltd.</u></strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>750
      Lexington Avenue, 20</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong>th</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
      Floor</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>New
      York, New York 10022</u></strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      40-F
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7): ____</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      N/A
</u></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><img src="xtlbio.jpg" alt="XTLBIO logo"></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br>&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">XTL
      Biopharmaceuticals to Present at the </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">9</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>th</sup></font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">
      Annual
      BIO CEO &amp; Investor Conference</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NEW
      YORK, NEW YORK,</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>February
      8, 2007 </strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
      XTL
      Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) announced today
      that
      Ron Bentsur, the Company&#8217;s Chief Executive Officer, is scheduled to present at
      the 9th Annual BIO CEO &amp; Investor Conference. Mr. Bentsur will present an
      overview of the Company including an overview of Bicifadine, the Company&#8217;s
      recently in-licensed late-stage clinical compound for the treatment of
      neuropathic pain. Mr. Bentsur&#8217;s presentation will take place on Wednesday,
      February 14th, 2007 at 3:00 pm Eastern Standard Time, at the Waldorf Astoria
      Hotel in New York City. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A
      live
      audio webcast of Mr. Bentsur's presentation will be available at: </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=XTLB&amp;item_id=1475520.
      </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An
      archived version of the webcast will be available following the conclusion
      of
      the live presentation.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
      XTL BIOPHARMACEUTICALS LTD.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      Biopharmaceuticals Ltd. (&#8220;XTL&#8221;) is engaged in the acquisition, development and
      commercialization of therapeutics for the treatment of neuropathic pain and
      hepatitis C. XTL is developing Bicifadine, a serotonin and norepinephrine
      reuptake inhibitor, for the treatment of neuropathic pain. In addition, XTL
      is
      developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the
      hepatitis C virus polymerase. XTL-2125 is currently in a Phase 1 clinical trial
      in patients with chronic hepatitis C. XTL is also developing XTL-6865 - a
      combination of two monoclonal antibodies against the hepatitis C virus -
      presently in Phase 1 clinical trials in patients with chronic hepatitis C.
      XTL&#8217;s
      hepatitis C pipeline also includes several families of pre-clinical hepatitis
      C
      small molecule inhibitors. &#160;XTL also has an active in-licensing and
      acquisition program designed to identify and acquire additional drug candidates.
      XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges
      (NASDAQ: XTLB; LSE: XTL; TASE: XTL).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      +1-(212)-531-5960</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>XTL
              BIOPHARMACEUTICALS LTD.</strong></font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:
              February 8, 2007</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/&#160;Bill
              Kessler</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%"><font size="2">Bill
              Kessler</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director
                of Finance</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>xtlbio.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 xtlbio.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!,`-P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@!*,
MTAKY7\8^,=0\6ZO/))<3+IHD_P!%M2=J(HR%)4$C?@G)YZD#C`KIPN%EB)-)
MVL95:RIJ[/JD45Y%\'?&>HZM-=Z'JEQ+=20Q^?!/*=S[=P#JS$Y/+*1P?XN<
M`"O7:RK494IN$BJ=13CS(6BBC-9EA1110`4444`%%&:*`"BBB@`HI,CUI:`"
MBBB@`HHHS0`4444`%%%%`!1110`W(Q7B'Q9BU_P]J\.HZ;K.K1:=?9W(E[+L
MBF')`YPJD<@9[-C``%>X8%9'B/1(/$6@7NE7#;4N(]H;!.QARK8!&<,`<9YQ
MBML-55.HI25UU,JL.:-EN?-5AXZ\3Z=?P7:ZW?3F)MWE7%P\L;CN&4GD$?B.
MH(.#7H6M_#*+QEL\3>%[^&*/4L7$D%T3A6;)<[UW8;=P4P<'=R,`5Y1JNEW6
MC:M=Z;>)MN+:0QO@$!L=&&0#M(P0<<@@UZ=\%O%<L&H2^&[J9V@F4R6:DDB-
MQEG4<<!AEN2`"I[M7N8J#A#V^'T:_%'#2:E+DJ?TSJ;?2M/^$/@G4KY;C[5J
M$V`))!M$TG(C0)N^Z,DG!)QN/8`>)_\`"6^)O^ABU;_P-E_^*KJ?BSXJEUOQ
M1+I<$S_V=IS>6(P3M>89#L1@<@DH.OW21]XU3^&?A-O$_B>.6:-'TVP99;H,
M1\YY*)M(.X$KR,8V@\@D9FA3C3HNO7U;U_R0ZDN::A3V1UT*>(]*^#6J:U?Z
MSJ)O;WR)+9C>.YAA,B;2#G*LP9LX/3:#@Y%>:_\`"6^)>WB+5O\`P-E_^*KZ
MEU?2+'7-+FTW48?.M)MN^/>RYPP8<J0>H'>N9_X5/X)Z?V+S_P!?4W_Q=<>'
MQM&*E[2.K=]$C:I0F[<KV1\__P#"7>)O^ABU;_P.E_\`BJ7_`(2WQ-_T,6K?
M^!TO_P`57HOQ5\$^'O#7ABVO-(T_[-.]ZD3/Y\CY4HY(PS$=5'Y5Y":]7#RH
MUX<\8Z>B..HIPERMFS_PEWB;_H8M6_\``Z7_`.*H_P"$N\3?]#%JW_@=+_\`
M%5[_`/\`"I_!/;1/_)J;_P"+KF/B%\/?"^A^!]1U+3=,\FZB\K9)]HE;;F1%
M/#,1T)[5RPQV&G)04-]-E_F;RH54FV]O4\F_X2[Q+_T,6K?^!LO_`,57TYX4
MFEG\(:+//(\LTEC`[R.Q9F8QJ223U)-?)6>*^M/!W_(DZ#_V#K?_`-%K6.:T
MX0C'E74K"-N3N;E!Z&BD/0UXQWL\LU+4KZ/5;U5OKE56=PJK*P`&X\#FO45R
M5![XKR/51_Q-[W_KX?\`]"->GWNI6>G0J]U<+&".`>2>G0#D]1TKU,=37)34
M%J^WR/F,EKVJ5Y59:)K=Z+5E\&D.<]:YZU\8Z7<2;6:2W)(`\U<`Y]P2!^.*
MW(+B*XC$D,B2(W1D((/XBO/G2G#XE8]^CBJ-=?NYI^C,OQ3+)#X?N)(W:-UV
M89201\X[BLCP1=W-RU\)YY90NS;YC%L9W9QFNKN)HK>(RS2)'&HY9R`!^)J*
MVO;2[W?9;B*7;C=Y;`XSTSBM(U;4)4^7=[]CFJX;FQD:WM+65N7OOKO^A;I#
MF@\"LJ]UW3;&3R[FZ02?W5!8CIU`!QU'6L8PE)VBKL[:E6G2CS5))+S=C6I,
MUS]KXOTFX(#R/`Q;:!*F/QR,@#ZFM\,KKE3D4YTYP=I*Q%'$TJRO3DGZ,?11
M14&X4444`>0?&/P>;NQC\1Z?:[KF'Y;WRTY>/'$C<_P8P>"<'DX6O$H9I;>>
M.>&1XIHV#I(C%65@<@@CH0:^K?%NM:?H/AJ\O-2$4D/ELBV\IXN&(.(\8.=W
M0\'`R3P#7R?VKZ#*ZDYTW"6RV/-Q45&=UU)K.UGOKVWL[5/,N+B18HDR!N9C
M@#)X')[U]4>#_#D?A;PS9Z6FTS*N^X=<?O)3RQS@9&>!D9V@#M7S;X0\0-X8
M\3V>JB))(XVVS*8P[>6W#;,XPV,X((]#P2#]4V-W!?V-O>6SF2">-98GP1N5
MAD'!Y'![UAFTYWC'[/ZFF#C'5]2U1117C'<>7_'/_D3++_L()_Z+DKP#M7O_
M`,<_^1,LO^P@G_HN2OG_`+5]'EG^[_-GEXK^(?9_85Q7Q8_Y)IJ__;'_`-')
M7:]A7%?%C_DFFK_]L?\`T<E>%A_XT?5?F>A4_AOT/F7M7UIX._Y$G0?^P=;_
M`/HM:^2^U?6G@[_D2=!_[!UO_P"BUKULX^&/J<>"^)FY2'H:6D/0UX9Z#/(=
M5.-8OO\`KX?_`-"-;VEZ-=>)&.H:C=2>6#L7:H!8`=N,`9]`<G/2L'5?^0O?
M?]?#_P#H1KU.QMC:6%O;@[O*C";L8S@8SBO<QE9TJ,.3=]?NN?%95@UB<55]
MIK%/5=&[NU_0YBZ\#0B(_9;F02CD>;@@\=.`,<XYY^E8>AZK+H6IM!<%E@+%
M)DQG:PXW#'N.<=1Z\5Z9S7G/C.-$U[>JX:2%68YZG)'\@*PP=:5=NC5U31VY
MI@Z>"C'%89<KB_DSJ_%AW>&;DCIE/_0A6-X`^_J'TC_]FJUJ4WVCP`LA<NQB
MB#-NR2=RYR?KG-5?`7!U$^@C_P#9J4(VP4X]I?Y%U)J>;49KK&_X,M^)?$LN
MG2_8[/9YVW+NW.P'H`/[W?GVX.:QM"\*'4[9;R>XV6[9VJGWS@D')/`Y'O\`
MA6=?3#6/$3LK!5N)UC5@I^[D*#@^V#_A7J:C`XHJS>$I1C3TE+=D86FLSQ-2
MI6?-"#LET]3D+KP-#Y)^RW4@E'(\W#*>.G`&.<<\_2L/2M=O-#N?LTV7MT=E
MDAXRISR5/U'3.#SZYKTL5P/C>T6/4(+A<`S*0P"XR5QR3WX('X482LZTO8UM
M4RLTP4<'!8K"^ZX[VV:9W4$R7-O'-$=R2*&4^H(R*D/6L?PO*\WAVT:0Y8`I
MG&.%8@?H!6P>M>;57))Q[.Q[]"I[6C&IW2?WCL49[T5YQ\6/&;>'=&73+&=T
MU.^4[9(G`:&,$9;U!;E01C^(@@K3HTY59J$=V:SFH1<F>9_$_P`9MXGUYK.S
MF?\`LNR8HBAP4FD!(,HQU!'"\GCD8W$5C>"?##^+?$\&F[WCMU4RW,B8W)&O
MIGN257OC=G!`-<[7TS\-_";>$_"ZQ7$:+J5RWFW1!#;3T5-P'(4=LD;BV#@U
M]!B9QP=!0AOLO\SS:477J7D?/'B'19_#WB"^TFY.Z2VDVA\`;U/*M@$XRI!Q
MGC.*]5^"WBQI!)X7O)$"HIEL<@*>I,B9S\QR=P&"<;\G``JU\;?#7VG3;?Q%
M`O[VUQ!<\]8F;Y3R>SG&`,G?Z+7BEG=SV-[;W=J_EW%O(LL3X!VLIR#@\'D=
MZ4;8W#:[_DQN]"KIM^A]D45SW@_Q)'XI\,V>J)M$S+LN$7'[N4<,,9.!GD9.
M=I![UT-?/2BXR<7NCTDTU='F'QS_`.1,LO\`L()_Z+DKY_[5]`?'/_D3+/\`
M[""?^BY*^?\`M7T66?[O\V>9BOXA]G]A7%?%C_DFFK_]L?\`T<E=KV%<5\6/
M^2::O_VQ_P#1R5X6'_C1]5^9Z%3^&_0^9:^L_!__`").@_\`8/M__1:U\FXK
MJ[/XE>+[&R@L[75S';P1K%$GV>$[548`R4R>!WKW\PPD\0DH-:=SSL/5C3;;
M/J/-(>AKYE_X6OXV_P"@W_Y*P_\`Q%'_``M?QJ?^8W_Y*P__`!%>;_95?NOQ
M_P`CI^N0[,[W51_Q-[WU^T2?^A&O6U`V#'I7BME<3ZC:V]S,3+<W*+(Y"C+L
MP!.`/4GH*[S0/%-HME#:WK>3)%MC1N=KCH#GM[YX[_3HS"A.5.%E?E_K]#YK
M)<73HXFK&H[<ST;\F]/Q.QKSOQM_R'$S_P`^Z_\`H35TUYXHTNT4XN?.?:"$
MA^;/..O3\S7$VL5QXBUP"3EYFS*ZC`1!Z<''``&>^,USX"E.G)UIJR2.S.\5
M3K0CA:3YI2:V>WJ=+>QI!\.XU5=H,43$=>68$_J35?P%R=1^D?\`[-6UXL`7
MPQ<J.VS_`-"%8W@'[VH?2/\`]FIQES8.<GUE_D*I34,UH072-OP9S<2QZ?KJ
M)(^4M[H!F([*_)Q^%>L`\5P7C#298[UM212T$F`YSG8P&!]`0!^/X5I:/XMM
MIK=8M1D\NX!"^85.U_?CA??.!_(/%QEB*<*L->Y&65(8'$5<-6?+=W3>B:]3
MJ_TSUKA_'<R-<VD(;YT5F88Z`D`?R/Y5OW7B72K1-WVM)"0<+$=QX^G`_'%<
M'=3W'B#6L[<23L$C3)(5?\!R3^)J,!0DJGM9JR1MG>-ISH?5Z34I2:T6O6YW
M?A+GPS:_5_\`T,UN`\54LK;['806V[=Y4:INQC.!C.*G8X.*X*TU*<I+JV>W
MAH>RH0@^B2)*\^UKX3Z-X@UFZU6^U#4S<W#[FVO$J@````>7T``'//'))YKT
M`4M$*DZ;O!V9M*,9JS1YWI/P?\.Z/JUKJ4=QJ$\EK()8TFE39N'*D[4!X.#U
M[<Y'%>B=.U%)FBI4G4=YNXHQC#1(K7MI#J%C<6=RAD@GC:*5,D;E88(R.1P>
MU>='X&>&NU]JW_?V+_XW7IU+3IUIT_@=@E",]T<CX1\!:?X-N+F33KR]D6Y5
M5ECG9&4E2=IX0$$9;OCGITQUU%%3.4IOFD[LJ,5%61S_`(L\)V/C#3(K#4);
MB***83!H&"MN"LO<'C#&N0_X49X:_P"?_5O^_L7_`,;KT^D-:0KU8+EA*R(=
M.$G=H.PK*\0Z#;>)=#N-)O))DMY]N]H2`XVL&&"01U4=JUJ*Q3<;-;EM)JQY
MA_PHSPU_S_:M_P!_8O\`XW1_PHSPU_S_`&K?]_8O_C=>H45T_7*_\[,O84^Q
MY?\`\*,\-?\`/]JW_?V+_P"-T?\`"C/#7_/]JW_?V+_XW7J%%'URO_.P]A3[
M')Z=X$T[3#:B*>Z=;;;LWLO.W&,X4>E3ZCX1LK^XDG1I()''(3&W=ZD?SP1G
MZ\UT?:E[5'UJKS<W,[G.\NPKBX."LW?YG&V_@.-9"9[YW3'`C38<_4D_RKH]
M/TNSTR-EM(!&'.6Y))_$\U<0YS3AR*=7$5:FDY7'A\OPV&?[J"3[[O[V4]3L
M(]2L'M)2RI)C)4@'@@]_I531M"M]%\XP22/YNW=O(XQG&,`>M:O=:=VK/GFH
MN%]&;2H4I555:]Y:7(Y(TF0I(H92""",@CWKF;OP192[VMI98#Q@9WJ/7@\G
M\_\`"NJZ=**=.M.F[P=B<1@Z.(5JL4SCK?P'&KDW%Z[IC@1H%.?J2?Y5T5CI
M-EIRC[+;I&P!&[&6()SRQY/YU=!I]74Q%6I\<KF>'R_#8;6G!)]]W][%HHHK
$`[3_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
